Using its advanced AI platform to explore immune cell activity and metabolic function, Landos has identified novel pathways including NLRX1 and PLXDC2. The NLRX1 pathway works to decrease reactive oxygen species and downregulate effector immune responses. The PLXDC2 pathway leads to the production of IL-10 and prevention of oxidative stress when activated.
Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class, oral therapeutics for patients with autoimmune disease.
Landos was established as an incredibly productive research engine, with a current portfolio of two novel targets anchoring libraries of immunometabolic modulation pathways, including four potentially first-in-class, once-daily, oral therapies targeting eight indications in the immunology space, including our clinical stage program NX-13 for Ulcerative Colitis and Crohn’s Disease.
For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Landos’ therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune disease by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.